remain of patients is you, very on Vanda I time Kevin. we the but lives will we first to unusual all a business. This for update and us. the provide we Good of at on can you innovate focused the better an us, Thank for thank joining ways everyone, afternoon, serve. diagnose
the the both commercial with We're in performance very and HETLIOZ Fanapt quarter. for happy first
reported testament grew XX% today products and we value our The quarter in quarter XXXX. to earlier of As the and more hard Fanapt our over the by the the of bring associates. that work than HETLIOZ first first sales
of has While that the and and the due resulted pandemic patient method in in visits in disruption doctors office serving doctor patients person COVID-XX and changed availabilities. to
force prescribers In early model. to a March, our and the remotely sales to we adapt serving instructed teleworking begin
as have to all. Our of sales their our force adaptability we of mindful services and ways still found extend do new to has both prescribers safety our some the flexibility great and and so patients
of office people in at which Stay on on services some delivery are changing and prescriptions. impact The are home medical closures orders seeking the the refills services. medical more have of disruption may patient new by does starts receiving it and medical dynamic than existing
by unclear the On we to better with whether in the adherence. offset starts new adherence. translate may access which this In better patient time impact experienced is such it expected side, maybe HETLIOZ at higher
sales also disruption any seeking of Similarly new too receiving for of effect have and whether services, net and is marketing know Fanapt, medical it practices. This reality on patients for the to however early treatment. negative new the number on is opportunities our will creating
continue the each in earlier new we towards that performance first has we patient our remain momentum customized goals awareness, this disruption education Vanda and year. its services. At current for commercial the remote in its this of optimistic of strong positions Vanda tremendous the delivery in to set in quarter proximity implemented physician well time, that of weather a number and
future business and updates nature continuously as evaluating will Of provide the appropriate. evolving pandemic, COVID-XX and the course, rapidly on of due to impact we're we the operations
onto pandemic clinical development studies. the conduct our the challenges of clinical has Now new created clearly for pipeline,
primary is of safety our as of the employees as that our and well patients in assuring goal Our collaborators.
pause As to such our and new treatment and remote after screenings careful we to clinical participants. of evaluation decided continue randomizations of all but evaluation the of existing programs, trial
This patients believe approach dermatitis, phase are and clinical patients, this for HETLIOZ time delayed continuation do will existing of begin safe motion including other studies clinical we to has with the gastroparesis so. bipolar it planned and at and is allowed hold in until for our disorder we for not Fanapt recruiting studies Tradipitant atopic sleep sickness,
the appreciate teams. We the their research investigators study very much of clinical flexibility of as and that well as participants
On pursuit continue HETLIOZ disorder in namely on with lag people the jet and with Smith-Magenis two indications, new of our the of discussions front, the our FDA Syndrome. regulatory we for approval treatment
adequacy We're to expedient these the need soon in working robustness our identify of confident as we're to bring data and people and as possible. to them products paths who
impact evaluate to last able the fight we to expertise areas has to Over COVID-XX. two be an months, scientific may Vanda and led utilize against the where our effort
previously smoke infection announced, double-blind study study ARDS demonstrated our with ARDS. animal previously Acute in of NK-X or the role Distress Syndrome Respiratory Respiratory for patients in after Distress placebo is we As in The controlled inhalation preventing a is system Syndrome. Acute or of models and ODYSSEY arsenal treating COVID-XX a induced viral Tradipitant sepsis, this study
in and on ongoing expect we rates quarter. recruitment results third dependent is the study of The
in our CALYPSO role the and disease the of We human play study. variations progression. that announced The also aims CALYPSO COVID-XX study study infection genetic initiation to
the the of conducted Washington, of will of of collaboration and and number with about participants Medicine University School sites enrolling with participation be CALYPSO of Virology. also Department a X,XXX goal a the of with a clinical will involve
COVID-XX COVID-XX the combat pandemic. spirit data and as the genome hope including viral make patients, targets. sequencing we to worked world significant gain well In insights CALYPSO both genome as to to human for therapeutic scientists include of across available sequencing, we've aim as novel the we publicly will potential primary researchers collaboration, the of the to
small at the established of potential is for Separately, in virus and Illinois Such slowing cell. of enables the inhibiting critical replication. University system enzyme and viral such, and a down that molecule the host enabling viral host of cathepsin-L, temporary a with partnership we processing disabling compounds Chicago the host propagation research have inhibitors at the identifying aimed
summary emerging the position, impressive always of determination a Vanda devote lives talent with strength, of salvaging this we associates the robust in as our In and financial unprecedented performance, is have pipeline, done. with pain healthy times, improving a commercial to people midst the R&D a to of
turn our now Financial will Kevin to the our results. to Kevin? discuss over Chief I financial Officer first quarter call Moran,
